Evidence map›Paper›PMID 26472629›Full record

ArticleThe American journal of psychiatry2016

Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data.

Eric A Epping, Ji-In Kim, David Craufurd, Thomas M Brashers-Krug, Karen E Anderson, Elizabeth McCusker, Jolene Luther, Jeffrey D Long, Jane S Paulsen, PREDICT-HD Investigators and Coordinators of the Huntington Study Group

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed.

  1. Trial
  2. Psychiatry in neurodegenerative disease: toward a unified neurobiological framework.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  3. Article
  4. Exploring huntington's disease from a neurodevelopmental perspective.International journal of biological sciences · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. [Gene Therapy for Huntington Disease].Fortschritte der Neurologie-Psychiatrie · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eric A EppingFrom the Departments of Psychiatry and Neurology, Carver College of Medicine, University of Iowa, Iowa City; the Department of Biostatistics, College of Public Health, University of Iowa, Iowa City; the Department of Psychology, University of Iowa, Iowa City; the Institute of Human Development, University of Manchester, Manchester, U.K.; the Huntington Disease Care, Education, and Research Center and the Departments of Psychiatry and Neurology, MedStar Georgetown University Hospital, Washington, D.C.; and the Department of Neurology, Westmead Hospital, University of Sydney, Sydney, Australia.
Ji-In KimFrom the Departments of Psychiatry and Neurology, Carver College of Medicine, University of Iowa, Iowa City; the Department of Biostatistics, College of Public Health, University of Iowa, Iowa City; the Department of Psychology, University of Iowa, Iowa City; the Institute of Human Development, University of Manchester, Manchester, U.K.; the Huntington Disease Care, Education, and Research Center and the Departments of Psychiatry and Neurology, MedStar Georgetown University Hospital, Washington, D.C.; and the Department of Neurology, Westmead Hospital, University of Sydney, Sydney, Australia.
David CraufurdFrom the Departments of Psychiatry and Neurology, Carver College of Medicine, University of Iowa, Iowa City; the Department of Biostatistics, College of Public Health, University of Iowa, Iowa City; the Department of Psychology, University of Iowa, Iowa City; the Institute of Human Development, University of Manchester, Manchester, U.K.; the Huntington Disease Care, Education, and Research Center and the Departments of Psychiatry and Neurology, MedStar Georgetown University Hospital, Washington, D.C.; and the Department of Neurology, Westmead Hospital, University of Sydney, Sydney, Australia.
Thomas M Brashers-KrugFrom the Departments of Psychiatry and Neurology, Carver College of Medicine, University of Iowa, Iowa City; the Department of Biostatistics, College of Public Health, University of Iowa, Iowa City; the Department of Psychology, University of Iowa, Iowa City; the Institute of Human Development, University of Manchester, Manchester, U.K.; the Huntington Disease Care, Education, and Research Center and the Departments of Psychiatry and Neurology, MedStar Georgetown University Hospital, Washington, D.C.; and the Department of Neurology, Westmead Hospital, University of Sydney, Sydney, Australia.
Karen E AndersonFrom the Departments of Psychiatry and Neurology, Carver College of Medicine, University of Iowa, Iowa City; the Department of Biostatistics, College of Public Health, University of Iowa, Iowa City; the Department of Psychology, University of Iowa, Iowa City; the Institute of Human Development, University of Manchester, Manchester, U.K.; the Huntington Disease Care, Education, and Research Center and the Departments of Psychiatry and Neurology, MedStar Georgetown University Hospital, Washington, D.C.; and the Department of Neurology, Westmead Hospital, University of Sydney, Sydney, Australia.
Elizabeth McCuskerFrom the Departments of Psychiatry and Neurology, Carver College of Medicine, University of Iowa, Iowa City; the Department of Biostatistics, College of Public Health, University of Iowa, Iowa City; the Department of Psychology, University of Iowa, Iowa City; the Institute of Human Development, University of Manchester, Manchester, U.K.; the Huntington Disease Care, Education, and Research Center and the Departments of Psychiatry and Neurology, MedStar Georgetown University Hospital, Washington, D.C.; and the Department of Neurology, Westmead Hospital, University of Sydney, Sydney, Australia.
Jolene LutherFrom the Departments of Psychiatry and Neurology, Carver College of Medicine, University of Iowa, Iowa City; the Department of Biostatistics, College of Public Health, University of Iowa, Iowa City; the Department of Psychology, University of Iowa, Iowa City; the Institute of Human Development, University of Manchester, Manchester, U.K.; the Huntington Disease Care, Education, and Research Center and the Departments of Psychiatry and Neurology, MedStar Georgetown University Hospital, Washington, D.C.; and the Department of Neurology, Westmead Hospital, University of Sydney, Sydney, Australia.
Jeffrey D LongFrom the Departments of Psychiatry and Neurology, Carver College of Medicine, University of Iowa, Iowa City; the Department of Biostatistics, College of Public Health, University of Iowa, Iowa City; the Department of Psychology, University of Iowa, Iowa City; the Institute of Human Development, University of Manchester, Manchester, U.K.; the Huntington Disease Care, Education, and Research Center and the Departments of Psychiatry and Neurology, MedStar Georgetown University Hospital, Washington, D.C.; and the Department of Neurology, Westmead Hospital, University of Sydney, Sydney, Australia.
Jane S PaulsenFrom the Departments of Psychiatry and Neurology, Carver College of Medicine, University of Iowa, Iowa City; the Department of Biostatistics, College of Public Health, University of Iowa, Iowa City; the Department of Psychology, University of Iowa, Iowa City; the Institute of Human Development, University of Manchester, Manchester, U.K.; the Huntington Disease Care, Education, and Research Center and the Departments of Psychiatry and Neurology, MedStar Georgetown University Hospital, Washington, D.C.; and the Department of Neurology, Westmead Hospital, University of Sydney, Sydney, Australia.
PREDICT-HD Investigators and Coordinators of the Huntington Study Group

Funding

NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON'S DISEASER01NS040068 · NINDS · UNIVERSITY OF IOWA · PI PAULSEN, JANE S · 2001 to 2013
$48.5M
University of Iowa Clinical and Translational Science ProgramUL1TR000442 · NCATS · UNIVERSITY OF IOWA · PI ROSENTHAL, GARY E · 2012 to 2013
$10.0M
Cognitive and functional brain changes in preclinical Huntington's disease (HD)R01NS054893 · NINDS · UNIVERSITY OF IOWA · PI PAULSEN, JANE S · 2007 to 2011
$2.0M
NCATS NIH HHS 2 UL1 TR000442-06NCATS NIH HHS UL1 TR000442NINDS NIH HHS 5R01NS040068NINDS NIH HHS 5R01NS054893NINDS NIH HHS R01 NS040068NINDS NIH HHS R01 NS054893
6 · The paper itself

Abstract

objectivePsychiatric symptoms are a significant aspect of Huntington's disease, an inherited neurodegenerative illness. The presentation of these symptoms is highly variable, and their course does not fully correlate with motor or cognitive disease progression. The authors sought to better understand the development and longitudinal course of psychiatric manifestations in individuals who carry the Huntington's disease mutation, starting from the prodromal period prior to motor diagnosis.

methodLongitudinal measures for up to 10 years of psychiatric symptoms from the Symptom Checklist-90-Revised were obtained from 1,305 participants (1,007 carrying the Huntington's disease mutation and 298 without [classified as controls]) and 1,235 companions enrolled in the Neurobiological Predictors of Huntington's Disease (PREDICT-HD) study. Participants with the mutation were stratified into three groups according to probability of motor diagnosis within 5 years. Using linear mixed-effects regression models, differences in psychiatric symptoms at baseline and over time between the mutation-positive groups and the controls were compared, as well as between ratings by mutation-positive participants and their companions.

resultsNineteen of 24 psychiatric measures (12 participant ratings and 12 companion ratings) were significantly higher at baseline and showed significant increases longitudinally in the individuals with the Huntington's disease mutation compared with controls. The differences were greatest in comparisons of symptom reports from companions compared with self-reports, especially in participants who were closest to motor diagnosis.

conclusionsThe results indicate that psychiatric manifestations develop more often than previously thought in the Huntington's disease prodrome. Symptoms also increase with progression of disease severity. Greater symptom ratings by companions than by mutation-positive participants suggest decreasing awareness in those affected.

Indexed as

Interpersonal RelationsProdromal SymptomsAdultAnxietyCase-Control StudiesCompulsive BehaviorDepressionDisease ProgressionFemaleHostilityHumansHuntington DiseaseLinear ModelsLongitudinal StudiesMaleMiddle Aged

Identifiers

PMID26472629
PMCPMC5465431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.